Figure 1
High expression of EZH2 is associated with poor patient outcomes and features of high-risk and proliferative disease. (a) Box and whisker plot showing EZH2 expression in UAMS data set (MGUS n=114, SMM n=163, MM n=1344) Log 2 expression values. One-way analysis of variance (F ratio 84.53, P<2e-16) followed by Tukey’s multiple comparison test demonstrated significant difference between MGUS and MM (adj. P⩽0.00001) and between SMM and MM (adj. P⩽0.00001). (b) Kaplan–Meier curves showing OS (i) in the MyIX data set comparing high EZH2 mRNA (>8.24, log 2 expression value, n=31) to all others (n=228). Median OS 2.37 years (95% CI (1.12, 3.64)) vs 3.76 (95% CI (3.27, 4.28)). Logrank P=0.00067 and (ii) in the UAMS-TT data set comparing high EZH2 (>9.32, log 2 expression value n=254) to all others (n=967). Median OS 4.61 years (95% CI (3.77, 6.06)) vs 12.1 (95% CI (10.8, 13.5)). Logrank P=4.4e-20. (c) Box and whisker plot showing the EZH2 expression across the UAMS molecular subgroups. Log 2 expression values. PR mean expression 9.56 vs all other 8.48, one-sided Welch’s t-test P=5.953e-42. (d) Box and whisker plots showing the EZH2 expression across UAMS GEP70 high- vs low-risk patients. High-risk GEP70 had a higher mean expression of EZH2 (9.61 vs 8.46, one-sided Welch’s t-test P-value=1.993e-40). GEP70 scores also significantly correlated with EZH2 expression (Pearson correlation of 0.611). (e) High-density scatter plot demonstrating the correlation between the EZH2 expression and the gene expression-defined proliferation index. R=0.79, P<0.0001.
